RIPK1/RIP1 Antibody - BSA Free

Western Blot: RIPK1/RIP1 AntibodyBSA Free [NBP1-77077]

Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - Rat kidney tissue lysate with RIPK1 antibody at 1 ug/mL.

Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077]

Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Mouse kidney tissue with RIPK1 antibody at 2.5 ug/ml.

Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077]

Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Staining of mouse kidney tissue with antibody at 2.5 ug/ml.

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta-actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta-actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] -

Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.